Spark Therapeutics Inc (ONCE) Announces Earnings Results

Spark Therapeutics Inc (NASDAQ:ONCE) released its quarterly earnings results on Tuesday. The biotechnology company reported ($1.70) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.36) by $0.34. The firm had revenue of $1.27 million for the quarter, compared to analysts’ expectations of $1.35 million. Spark Therapeutics had a negative net margin of 441.05% and a negative return on equity of 28.28%. The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.95) EPS.

Shares of Spark Therapeutics (NASDAQ:ONCE) traded down 1.88% during midday trading on Friday, hitting $54.79. 58,304 shares of the stock were exchanged. Spark Therapeutics has a 12-month low of $35.07 and a 12-month high of $65.99. The company’s market cap is $1.71 billion. The firm has a 50-day moving average price of $55.13 and a 200-day moving average price of $56.28.

Earnings History for Spark Therapeutics (NASDAQ:ONCE)

A number of equities analysts recently commented on the stock. Cantor Fitzgerald reiterated a “buy” rating and set a $94.00 target price on shares of Spark Therapeutics in a research note on Thursday, February 23rd. Jefferies Group LLC set a $59.00 target price on shares of Spark Therapeutics and gave the stock a “hold” rating in a research note on Wednesday, February 22nd. Stifel Nicolaus boosted their target price on shares of Spark Therapeutics from $73.00 to $76.00 and gave the stock a “buy” rating in a research note on Thursday, February 23rd. Wedbush reiterated an “underperform” rating and set a $28.00 target price on shares of Spark Therapeutics in a research note on Wednesday, February 22nd. Finally, JPMorgan Chase & Co. set a $82.00 price target on shares of Spark Therapeutics and gave the company a “buy” rating in a research report on Wednesday, February 22nd. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the stock. Spark Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $68.31.

In related news, Director Anand Mehra sold 41,910 shares of the business’s stock in a transaction dated Monday, February 27th. The stock was sold at an average price of $65.02, for a total value of $2,724,988.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Stephen W. Webster sold 10,000 shares of the business’s stock in a transaction dated Tuesday, April 25th. The shares were sold at an average price of $55.18, for a total value of $551,800.00. Following the completion of the transaction, the chief financial officer now directly owns 4,398 shares of the company’s stock, valued at approximately $242,681.64. The disclosure for this sale can be found here. In the last ninety days, insiders sold 190,796 shares of company stock valued at $12,057,667. 9.60% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ONCE. BlackRock Inc. boosted its position in Spark Therapeutics by 11,332.0% in the first quarter. BlackRock Inc. now owns 1,840,214 shares of the biotechnology company’s stock worth $98,158,000 after buying an additional 1,824,117 shares in the last quarter. Baker BROS. Advisors LP acquired a new position in Spark Therapeutics during the third quarter worth about $79,180,000. Wellington Management Group LLP boosted its position in Spark Therapeutics by 119.5% in the first quarter. Wellington Management Group LLP now owns 808,782 shares of the biotechnology company’s stock worth $43,140,000 after buying an additional 440,287 shares in the last quarter. Wells Fargo & Company MN boosted its position in Spark Therapeutics by 131.8% in the first quarter. Wells Fargo & Company MN now owns 522,894 shares of the biotechnology company’s stock worth $27,891,000 after buying an additional 297,277 shares in the last quarter. Finally, Norges Bank acquired a new position in Spark Therapeutics during the fourth quarter worth about $8,232,000. Hedge funds and other institutional investors own 83.97% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/05/19/spark-therapeutics-inc-once-announces-quarterly-earnings-results-updated.html.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

5 Day Chart for NASDAQ:ONCE

Receive News & Ratings for Spark Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply